PT-141 (10 mg vial)
Once daily subcutaneous protocol for sexual and cosmetic research.
PT-141, approved as bremelanotide, is a melanocortin-4 agonist that works sexual arousal through the central nervous system rather than blood flow, and it carries FDA approval for hypoactive sexual desire disorder in women. The protocol below is as-needed subcutaneous dosing, taken well before activity.
Quick answer: at the standard 10 mg + 1 mL reconstitution, a 1.5 mg dose of PT-141 draws 15 units (0.15 mL) on a U-100 insulin syringe, once daily subcutaneous.
Get PT-141 → code PEPDOSE
Protocol overview
Dosing & reconstitution
Frequency: Once daily subcutaneous
Typical duration: 8-12 weeks
Reconstitution: 10 mg vial + 1 mL bacteriostatic water = 10 mg/mL. Units below are for a U-100 insulin syringe at this concentration.
| Phase | Dose | Units per injection |
|---|---|---|
| Weeks 1-8 | 500 mcg | 5 units (0.05 mL) |
| Weeks 9-12 | 1 mg | 10 units (0.1 mL) |
| Weeks 13-16 | 1.5 mg | 15 units (0.15 mL) |
Units = (dose ÷ concentration) × 100 on a U-100 syringe. Change the vial size or water volume and the calculator redoes all of this for you.
Track this protocol → Free account · log doses, rotate sites, never lose your history
PT-141 dosing schedule
From the approved label. Bremelanotide is FDA-approved as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Note it is an as-needed product with an explicit frequency ceiling — that limit is part of the protocol, not an afterthought.
| Phase | Amount | Frequency | Notes |
|---|---|---|---|
| Approved use | 1.75 mg | As needed, subcutaneous, at least 45 minutes before anticipated activity | The single approved amount. |
| Labelled maximum | 1 dose per 24 hours | No more than 8 doses per month | The frequency ceiling is part of the approved labelling. |
Study length: As-needed use rather than a course. The label caps use at one dose in 24 hours and no more than eight per month.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for PT-141: 10 mg.
- Wipe the stoppers of both vials with an alcohol swab and let them dry.
- Draw the bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the peptide vial — never straight onto the powder.
- Swirl gently until the solution is clear. Do not shake; foaming and agitation damage peptides.
- Label the vial with the date and concentration, and refrigerate at 2–8 °C protected from light.
Worked example at the calculator defaults: 10 mg + 2 mL of bacteriostatic water = 5 mg/mL, so on a U-100 insulin syringe 1 unit = 50 mcg of PT-141. Change either input and the calculator redoes this for you.
Storage and stability
Supplies math
Whatever amounts your research uses, the planning arithmetic is the same. The calculator runs all of this per compound.
Supplies by protocol length
Based on the maintenance dose above (1.5 mg, once daily subcutaneous) and a 10 mg vial reconstituted with 1 mL.
| Duration | Injections | Vials | Syringes | Bac water | Swabs |
|---|---|---|---|---|---|
| 8 weeks | 56 | 10 x 10 mg | 62 | 1 x 10 mL | 112 |
| 12 weeks | 84 | 14 x 10 mg | 93 | 2 x 10 mL | 168 |
| 16 weeks | 112 | 19 x 10 mg | 124 | 2 x 10 mL | 224 |
Syringe count includes ~10% spares. Swabs = 2 per injection (stopper + site). Vial count assumes the full maintenance dose for the entire duration.
Important notes
Practical considerations for consistency and safety.
- Use a new sterile insulin syringe for each injection and dispose in a proper sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and avoid lipohypertrophy.
- Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
- Administer at the same time each day for consistent levels. Setting a daily reminder helps maintain the schedule.
- The 10 mg vial size is standard for this compound. Reconstitute with 1 mL bacteriostatic water for a convenient concentration.
How PT-141 works
A melanocortin-receptor agonist derived from the alpha-MSH analog melanotan II. It acts centrally on MC4 receptors rather than on the vascular system, which is what distinguishes it mechanistically from PDE5 inhibitors.
Benefits & side effects
Potential benefits
- Melanocortin agonist for sexual function
- Acts centrally through brain pathways, not vascular
- FDA-approved version exists (bremelanotide)
- Both male and female applications studied
Possible side effects
- Nausea (common, especially at first)
- Facial flushing
- Blood pressure changes possible
- Skin darkening with repeated use
This list reflects published literature and community reports. Individual responses vary. Not medical advice.
Bloodwork worth tracking
The community-standard practice is a baseline panel before starting, a recheck 8 to 12 weeks in, and another after time off. For PT-141, the markers most worth watching:
CMPCBCblood pressure
Typical time off: Use as needed; 2-4 wk breaks
Lab panels are how a research protocol stays honest: numbers move before symptoms do. Interpretation belongs with a clinician. Not medical advice.
Lifestyle factors
None of the literature above was run on a background of poor sleep and no protein. These variables move outcomes more reliably than any compound on this site.
- Protein in the 1.6 to 2.2 g/kg range preserves lean mass through any body-composition phase.
- Resistance training 2 to 4 days per week plus 150+ minutes of weekly aerobic work reinforces whatever the protocol is doing.
- Sleep is the recovery window: 7 to 9 hours at consistent times.
- Hydration matters more than usual on compounds with GI or flushing effects: 2 to 3 liters daily.
- Track the variables that matter: weigh-ins, measurements, photos, and labs at sensible intervals.
Subcutaneous technique and practical notes
General best practice from clinical injection guidance — the same fundamentals nurses are taught, none of it specific to any compound.
References
Quick answers
How many syringe units is a 1.5 mg dose of PT-141?
At the standard reconstitution of 10 mg with 1 mL bacteriostatic water (10 mg/mL), a 1.5 mg dose draws 15 units (0.15 mL) on a U-100 insulin syringe.
How do you reconstitute PT-141?
Add 1 mL of bacteriostatic water to the 10 mg vial for 10 mg/mL. Inject the water slowly down the inside wall of the vial, swirl gently without shaking, and refrigerate at 2 to 8 °C after mixing.
How long does a 10 mg vial of PT-141 last?
About 6 maintenance doses of 1.5 mg, roughly 0.9 weeks at once daily subcutaneous.
Does PT-141 have human trial data?
Yes. The dosing on this page is anchored to published human research (Bremelanotide (Vyleesi) prescribing information, HSDD indication).
How does PT-141 work?
A melanocortin-receptor agonist derived from the alpha-MSH analog melanotan II. It acts centrally on MC4 receptors rather than on the vascular system, which is what distinguishes it mechanistically from PDE5 inhibitors.
Sourcing PT-141
Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.
PT-141 at Summit Research Supply → Grade a COA first
Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.
